Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Cytokinetics (CYTK) PT Lowered to $85 at Jefferies

May 23, 2024 5:59 AM EDT

Jefferies analyst Akash Tewari lowered the price target on Cytokinetics (NASDAQ: CYTK) to $85.00 (from $95.00) while maintaining a Buy rating.

The analyst comments "CYTK announced a $500m raise + amended its terms w/ Royalty Pharma (incl. updated royalty structure for afi, loan related to Ome... More